CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review
- 1 January 2022
- journal article
- review article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 432, 120089
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patientAnnals of Oncology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- PD-1 and PD-1 ligands: from discovery to clinical applicationInternational Immunology, 2007
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationJournal of Experimental Medicine, 2000
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- CTLA-4 is a second receptor for the B cell activation antigen B7.Journal of Experimental Medicine, 1991